Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Unique Physique

Medro
Graded #252

Higher grade

vs+2
Unique Physique
Graded #290

Lower grade

The verdict

Medro takes it — 63.6/100 to 61.6/100, but only just.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and… Unique Physique is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueUnique Physique +28
50
78
Dose & formulationMedro +16
77
61
Clinical oversightMedro +9
71
62
Labs & monitoringMedro +2
52
50
FulfillmentMedro +45
92
47
Contract termsUnique Physique +22
33
55
Medro · left barUnique Physique · right bar

The numbers

MetricMedroUnique Physique
WeighScore63.6/10061.6/100
GradeCC
Scorecard rank#252#290
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Unique Physique

Graded #290 · C

Strengths

  • Legal entity disclosed (Unique Physique, LLC) with Louisiana governing law — better than opaque DTC competitors
  • Named medical director (Reena John, DO) — uncommon at this price tier
  • Brick-and-mortar clinic in Baton Rouge, LA offers an in-person option vs ship-only competitors
  • Transparent two-tier flat pricing ($195/mo and $325/mo) — no dose-escalation surprises
  • Brand-name routing option ($25/mo) sends an Rx to your own pharmacy for Wegovy/Zepbound/Ozempic/Mounjaro

Where it loses points

  • GLP-1 drug molecules aren't named on the pricing or service pages — you can't confirm what the $195/mo and $325/mo plans contain without calling
  • Pharmacy partner not named — can't verify licensure or 503A vs 503B status
  • No FDA compounded-medication disclaimer on any audited page
  • States served not listed — only "licensed clinicians in the patient's state"
  • Non-refundable per the Terms; medication not picked up within 60 days is discarded with no refund

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard